CD8A and non-small cell lung carcinoma: The potency to activate CD8+ T cells at baseline, as determined through ex vivo activation and intra-cellular cytokine production, discriminates responders from non-responders to immune checkpoint inhibition combined with stereotactic radiotherapy in our patient cohort with non-small-cell lung cancer.